PhillipCapital

Broker's Calls

Analysts keep ‘buy’ and ‘neutral’ calls on SATS following expected 1QFY2024 results

DBS's TP stood unchanged at $3.20 while PhillipCapital's TP stood at $2.51.

Broker's Calls

Analysts are mixed on Singapore banks; RHB remains 'neutral' while PhillipCapital maintains 'buy'

PhillipCapital is positive on all banks, while RHB names UOB as its sole buy.

Broker's Calls

Analysts mixed on Sea following 2QFY2023 earnings and re-pivot to accelerating Shopee growth

All analysts have kept their “buy” and “add” calls, but CGS-CIMB and PhillipCapital analysts have lowered their TPs accordingly.
PhillipCapital upgrades CDL to 'buy' on City Development, but lowers target price to $8.22 - THE EDGE SINGAPORE

Broker's Calls

PhillipCapital upgrades CDL to 'buy' on City Developments, but lowers target price to $8.22

This new target price is derived from a lower revalued net asset value (RNAV), with a 45% discount to RNAV of $14.94.
Analysts lower calls and TP on PropNex after larger than expected revenue contraction for 1HFY2023 - THE EDGE SINGAPORE

Broker's Calls

Analysts lower calls and TP on PropNex after larger than expected revenue contraction for 1HFY2023

Maybank Securities reiterates “buy” with lower TP of $1.15, but PhillipCapital downgrades to “accumulate” with lower TP of $1.16.
Raffles Medical's 1HFY2023 results likely to have set a new baseline of profitability, analysts keep 'buy' - THE EDGE SINGAPORE

Broker's Calls

Raffles Medical's 1HFY2023 results likely to have set a new baseline of profitability, analysts keep 'buy'

Raffles Medical is Maybank’s preferred pick in the healthcare sector.
Expanding your investment tools with options - THE EDGE SINGAPORE

Financially Savvy

Expanding your investment tools with options

By utilising options, investors can effectively manage risk by limiting potential losses
×